Definitive treatment TNM staging system PET scan Partial remission Tumor Maintenance chemotherapy Recurrence or relapse Neoadjuvant treatment Lymphoma Complete remission Antibody drug conjugate Performance status Palliation Grade 3, 4, or 5 Surgical margin Cancer Adenocarcinoma Tyrosine kinase inhibitors (TKIs) Pathological stage Minimal residual disease Sarcoma Monoclonal antibody Liquid tumor Cure Chemotherapy ECOG performance status Leukemia Adjuvant treatment Checkpoint inhibitor Cellular therapy Clinical stage Active surveillance Multiple myeloma Carcinoma Complementary therapy Refractory CTCAE Benign Definitive treatment TNM staging system PET scan Partial remission Tumor Maintenance chemotherapy Recurrence or relapse Neoadjuvant treatment Lymphoma Complete remission Antibody drug conjugate Performance status Palliation Grade 3, 4, or 5 Surgical margin Cancer Adenocarcinoma Tyrosine kinase inhibitors (TKIs) Pathological stage Minimal residual disease Sarcoma Monoclonal antibody Liquid tumor Cure Chemotherapy ECOG performance status Leukemia Adjuvant treatment Checkpoint inhibitor Cellular therapy Clinical stage Active surveillance Multiple myeloma Carcinoma Complementary therapy Refractory CTCAE Benign
(Print) Use this randomly generated list as your call list when playing the game. There is no need to say the BINGO column name. Place some kind of mark (like an X, a checkmark, a dot, tally mark, etc) on each cell as you announce it, to keep track. You can also cut out each item, place them in a bag and pull words from the bag.
Definitive treatment
TNM staging system
PET scan
Partial remission
Tumor
Maintenance chemotherapy
Recurrence or relapse
Neoadjuvant treatment
Lymphoma
Complete remission
Antibody drug conjugate
Performance status
Palliation
Grade 3, 4, or 5
Surgical margin
Cancer
Adenocarcinoma
Tyrosine kinase inhibitors (TKIs)
Pathological stage
Minimal residual disease
Sarcoma
Monoclonal antibody
Liquid tumor
Cure
Chemotherapy
ECOG performance status
Leukemia
Adjuvant treatment
Checkpoint inhibitor
Cellular therapy
Clinical stage
Active surveillance
Multiple myeloma
Carcinoma
Complementary therapy
Refractory
CTCAE
Benign